Liver Forum 20 was held on March 6th and 7th in Reston, VA.
Materials
Introductory Remarks and Program Overview
Welcome, Program Overview, and Acknowledgements
Edyth Dwyer, Forum for Collaborative Research
Opening Remarks
Veronica Miller, Forum for Collaborative Research
Becky Taub, Madrigal Pharmaceuticals
Session I: Patient Engagement Working Group
The Dr. Stephen Harrison Patient Advocacy Fellowship: Overview
Elena Samsonova, Fatty Liver Foundation
Patient Engagement in Drug Development: Leading Through Example (PEDDLE)- Platform Demonstration
Becca Freed* & Edyth Dwyer, Forum for Collaborative Research
Henry Chang, Fatty Liver Foundation
Michael Betel*, Fatty Liver Alliance
Rosemarie Sellati*, Regeneron
Open Discussion
All Meeting Participants
Session II: Industry Rapid Fire Updates
Session III: Liver Forum Working Group Updates
Non-MASH Liver Forum Program Updates: PCLD, PSC, ACLF
Richard Moreau*, EF CLIF
Jacqueline O'Leary*, Dallas VA Medical Center
Pamela Vig*, Mirum Pharmaceuticals
Pediatric MASH Working Group
Bryan Rudolph, Boehringer Ingelhiem
Session IV: Update on Phase 3 Trials and Beyond
SYNERGY NASH Design and Goals
Arun Sanyal, Virginia Commonwealth University
Resmetirom’s MAESTRO Phase 3 Program
Dave Soergel, Madrigal Pharmaceuticals
Novo Nordisk Update
Michelle Long, Novo Nordisk
Open Discussion
All Meeting Participants
Session V: Towards Validated Surrogate Endpoints: Data Science
Placebo Arm Database Project Update
Margot Yann, Forum for Collaborative Research
Data Overview
Veronica Miller, Forum for Collaborative Research
VCTE Prognosis Study Group
Vincent Wong*, The Chinese University of Hiong Kong
Global NIT Study Group
Georg Semmler*, Medical University of Vienna
Panel Discussion
Peter Mesenbrink, Novartis
Alejandro Schuler, University of California, Berkeley
Jeffrey Siegel, U.S. Food and Drug Administration
Session VI: Towards Validated Surrogate Endpoints: Biomarker Science
RLSE and Validated Surrogate Endpoints
Roberto Calle, FNIH Biomarkers Consortium
RLSE Development: Brief Experience from Rare Kidney Disease
Dave Soergel, Madrigal Pharmaceuticals
Biomarkers in Noncirrhotic MASH: What Is Our North Star?
Suneil Hosmane, Madrigal Pharmaceuticals
Panel Discussion
Lisa Boyette, Eli Lilly and Company
Céline Fournier, Echosens
Michelle Long, Novo Nordisk
Peter Mesenbrink, Novartis
Arun Sanyal, Virginia Commonwealth University
Alejandro Schuler, University of California, Berkeley
Jeffrey Siegel, U.S. Food and Drug Administration
Session VII: Collaborative Path Forward
Collaborative Path Forward
Veronica Miller, Forum for Collaborative Research
Arun Sanyal, Virginia Commonwealth University
Becky Taub, Madrigal Pharmaceuticals
Session VIII: Stretch Exercise
The Reinvention of Medicine with AI…and What That Means for the Life Sciences
Nick Gossen, Dandelion Health
Ziad Obermeyer*, University of California, Berkeley
Open Discussion
All Meeting Participants
Session IX: Definition of the Progression to Cirrhosis and Decompensated Cirrhosis
Progression to Cirrhosis- a Critical Analysis of the Endpoint
Arun Sanyal, Virginia Commonwealth University
Endpoints in MASH Cirrhosis Trials
Becky Taub, Madrigal Pharmaceuticals
Panel Discussion
Paolo Angeli*, University of Padova
Wayne Eskridge*, Fatty Liver Foundation
Reshma Shringarpure, Akero Therapeutics/Novo Nordisk
Session X: What's Next?
Wrap Up
Veronica Miller, Forum for Collaborative Research
Arun Sanyal, Virginia Commonwealth University
Becky Taub, Madrigal Pharmaceuticals
* Remote Participation